Essential oils
Eucalyptus oil and 1,8-cineole: airway pathways, NF-κB and evidence boundaries
Understand eucalyptol’s monoterpene chemistry, inflammatory signalling research and why a defined oral trial cannot validate inhaling or swallowing household oil.
A small steroid-sparing trial studied 1,8-cineole capsules in severe asthma. It does not make concentrated eucalyptus oil a replacement for inhalers or urgent respiratory care.
Compounds & molecular formulae
1,8-Cineole (eucalyptol)
C₁₀H₁₈O
A cyclic ether and major constituent of many eucalyptus oils.
PubChem compound record ↗α-Pinene
C₁₀H₁₆
A volatile terpene found in some eucalyptus and rosemary chemotypes; concentration is batch-specific.
PubChem compound record ↗An inflammatory pathway in context
- Inflammatory stimulus activates NF-κB
- COX-2 and cytokine genes are expressed
- 1,8-cineole is tested in cells, animals or capsules
- Clinical lung outcomes require a controlled trial
Mechanistic suppression of a pathway is not the same as opening the airway of a person with an asthma attack [1][2].
From aroma to molecule
Eucalyptus essential oil is a volatile mixture. 1,8-cineole (eucalyptol) is often a major constituent, but the percentage depends on species, plant part and distillation. A fresh sensation when inhaling a vapour is sensory; it does not establish bronchodilation or infection control. Concentrated eucalyptus oil can be toxic when swallowed and can irritate airways or skin.
The human 1,8-cineole study
Juergens and colleagues enrolled 32 people with steroid-dependent severe asthma in a double-blind placebo-controlled trial [1]. Participants took 200 mg 1,8-cineole three times daily in small-gut-soluble capsules for 12 weeks while oral steroid doses were reduced. The active group achieved a greater steroid reduction under the study protocol. This was a defined pharmaceutical-style preparation with clinician monitoring; it is not evidence to stop a prescribed inhaler, self-dose eucalyptus oil or treat an acute attack with aroma.
NF-κB and COX-2 experiments
Cell and animal studies continue to explore 1,8-cineole, including NF-κB phosphorylation, COX-2 expression and cytokines in airway models [2]. These studies are valuable for generating hypotheses and identifying measurable pathways. They frequently use purified compound doses or animal exposures that do not match topical, diffuser or retail products. The clinical endpoint—lung function, exacerbations, steroid use and adverse events—must be measured in comparable humans.
Use eucalyptus with respiratory caution
Keep concentrated oil away from children, eyes and the mouth. Do not ingest it or use it as emergency asthma treatment. Stop exposure if it causes coughing, wheeze, headache or irritation. If breathing is difficult, follow the person’s emergency plan and seek medical care. Enki’s product team can clarify bottle identity, intended use and ingredient documentation.
Sources & credits
- Juergens et al. Anti-inflammatory activity of 1,8-cineole in bronchial asthma (Respiratory Medicine, 2003) — Double-blind placebo-controlled human trial
- 1,8-Cineole via NF-κB/COX-2 in airway cells and mice (Frontiers in Immunology, 2026) — Recent cell and animal study
- NCCIH: Essential oils and aromatherapy safety — Authoritative safety overview